Wednesday, July 8, 2026

Patent intelligence · US

US 11993573

Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents

granted A61KA61K31/352A61K31/382A61K31/47
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 8,292
Patent details — US 11993573

Quick answer

US 11993573 (Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents) is held by The Board of Regents for Oklahoma State University. Status: granted. Granted May 28, 2024. Expires May 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
4
CPC classes
A61K, A61K31/352, A61K31/382, A61K31/47, A61P, A61P35/00

More from The Board of Regents for Oklahoma State University

Related pharmaceutical patents in our USPTO index.

  1. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Expires Sep 25, 2045

    granted
  2. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  3. US 12428416

    ERK inhibitors and uses thereof

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  4. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  5. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  6. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Expires Sep 25, 2045

    granted
  7. US 12427155

    Treatment for tau-related diseases

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  8. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    The Regents of the University of California · Expires Sep 25, 2045

    granted

Frequently asked questions

What is US patent 11993573?

US 11993573 (Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents) is held by The Board of Regents for Oklahoma State University. Status: granted. Granted May 28, 2024. Expires May 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11993573?

The Board of Regents for Oklahoma State University is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.

When does US 11993573 expire?

Our index shows an expiration date of May 23, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.